Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer

S. Leyvraz,J. Berlin,D. S. Hong,J. Deeken,B. Valentina,D. -Y. Oh,J. Patel,S. Nanda,N. Brega,B. H. Childs,D. M. Hyman,A. Drilon

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 15|浏览91

暂无评分

摘要

824Background: Tropomyosin receptor kinase (TRK) fusions arise from rearrangements of the neurotrophic tyrosine receptor kinase (NTRK) 1, 2, or 3 genes and an unrelated gene, creating constitutivel...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要